Importantly, our investigational clinical PRMT5 inhibitor PRT543 displayed significant in vivo efficacy when combined with olaparib in multiple preclinical CDX and PDX ovarian and breast cancer models. This evidence concerns the gene PRMT5 and breast carcinoma.